Predicting the effect of drug-gene and drug-drug-gene interactions on the pharmacokinetics of CYP2D6 substrates : leveraging the activity score system in physiologically based pharmacokinetic modeling
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Saarbrücken, Universität des Saarlandes, Dissertation, 2024
- Ereignis
-
Veröffentlichung
- (wo)
-
Saarbrücken
- (wer)
-
Saarländische Universitäts- und Landesbibliothek
- (wann)
-
2023
- Urheber
-
Rüdesheim, Simeon Matthias
- Beteiligte Personen und Organisationen
- DOI
-
10.22028/D291-41679
- URN
-
urn:nbn:de:bsz:291--ds-416792
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rüdesheim, Simeon Matthias
- Lehr, Thorsten
- Saarländische Universitäts- und Landesbibliothek
Entstanden
- 2023
Ähnliche Objekte (12)
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions : Application of Physiologically-Based Pharmacokinetic Modeling
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Functional phenotyping of the CYP2D6 probe drug codeine in the horse
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Phenotypic Models of Drug-Drug-Gene Interactions Mediated by Cytochrome Drug-Metabolizing Enzymes
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions : Application of Physiologically-Based Pharmacokinetic Modeling
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Functional phenotyping of the CYP2D6 probe drug codeine in the horse
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Phenotypic Models of Drug-Drug-Gene Interactions Mediated by Cytochrome Drug-Metabolizing Enzymes
The influence of pharmacogenetics on the clinical relevance of pharmacokinetic drug–drug interactions: drug–gene, drug–gene–gene and drug–drug–gene interactions
Model Informed Drug Development and Precision Dosing for Drug-Drug-Gene-Interactions : Application of Physiologically-Based Pharmacokinetic Modeling
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Functional phenotyping of the CYP2D6 probe drug codeine in the horse
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions